开能健康(300272) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was CNY 466,315,308.43, representing a 9.80% increase year-over-year[5] - Net profit attributable to shareholders decreased by 7.10% to CNY 25,207,354.41 for the same period[5] - The net profit after deducting non-recurring gains and losses was CNY 23,789,540.75, down 12.73% year-over-year[5] - Total operating revenue for the current period reached ¥1,355,645,119.71, an increase of 8.1% compared to ¥1,254,037,408.51 in the previous period[19] - Net profit for the current period was ¥119,451,627.92, representing a 9.3% increase from ¥109,643,066.89 in the previous period[20] - Total comprehensive income for the period reached CNY 116,797,170.62, an increase from CNY 107,145,756.59 in the previous period, representing a growth of approximately 6.14%[21] - Basic earnings per share increased to 0.1672 from 0.1486, reflecting a growth of about 11.6% year-over-year[21] Assets and Liabilities - Total assets increased by 8.87% to CNY 3,218,656,694.43 compared to the end of the previous year[5] - The company's total assets increased to ¥3,218,656,694.43, compared to ¥2,956,338,872.28, marking a growth of 8.9%[18] - Current liabilities rose to ¥1,316,394,100.83, up from ¥1,103,726,755.46, indicating a 19.3% increase[18] - The total liabilities decreased to ¥1,670,078,518.00 from ¥1,645,242,044.47, a slight reduction of 1.5%[18] - Long-term borrowings slightly increased to ¥65,686,587.70 from ¥65,511,233.27, showing a marginal rise of 0.3%[18] Cash Flow - The company's cash flow from operating activities for the year-to-date was CNY 196,449,677.83, a decrease of 7.69%[5] - Cash flow from operating activities generated a net amount of CNY 196,449,677.83, down from CNY 212,819,194.37, indicating a decrease of approximately 7.7%[23] - Total cash outflow from operating activities was CNY 1,247,662,172.11, compared to CNY 1,116,181,306.02 in the previous period, indicating an increase of approximately 11.8%[23] - Cash inflow from investment activities totaled CNY 547,313,560.79, significantly up from CNY 5,959,890.50, marking an increase of over 9,000%[23] - Cash flow from financing activities yielded a net increase of CNY 116,035,296.68, compared to a net outflow of CNY 113,083,615.29 in the previous period[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,993[13] - The largest shareholder, Qu Jianguo, holds 31.83% of shares, totaling 194,638,209 shares, with 145,978,657 shares pledged[13] - The total number of restricted shares held by Qu Jianguo is 145,978,657, which are subject to a lock-up period[15] - The total number of shares held by the top 10 unrestricted shareholders is 146,997,457[15] - There are no significant changes in the top 10 shareholders due to securities lending or borrowing[14] Financial Expenses and Investments - Financial expenses rose by 49.08% to CNY 16,794,628.06, primarily due to a decrease in foreign exchange gains[9] - The company reported a decrease in financial expenses to ¥16,794,628.06 from ¥11,265,300.04, a rise of 49.4%[20] - Investment activities generated a net cash inflow of CNY 63,159,837.33, a 210.45% increase compared to the previous period[10] Research and Development - Research and development expenses for the current period were ¥47,792,071.38, compared to ¥46,343,257.83, an increase of 3.1%[20] Strategic Developments - The company did not report any new strategies or product developments during the conference call[1] - The company has not disclosed any plans for market expansion or mergers and acquisitions in the call[14] - The company has no new products or technologies mentioned in the conference call[14] - The company has not yet audited its third-quarter financial report[25]